MariTide's development in obesity treatment is crucial, but concerns about its progress and competition from Novo and Lilly remain. Despite strong performance, Amgen's high debt levels and ...

Amgen Inc (NASDAQ:AMGN)., a leading biopharmaceutical company with a market capitalization of $155 billion, is at a pivotal juncture as it navigates the competitive landscape of innovative ...

MariTide Phase 3 studies to begin in first half of year FDA places hold on AMG 513 obesity drug trial Amgen's Q4 earnings beat estimates, revenue up 11% Feb 4 (Reuters) - Amgen (AMGN.O), opens new ...

(Reuters) - Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators ...

At the forefront of Amgen's growth strategy is its obesity program, headlined by MariTide. This potential blockbuster drug has garnered significant attention from analysts and investors alike.

(Reuters) - Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators ...

MariTide, Amgen's candidate for obesity treatment, has emerged as a focal point for investors. Phase II topline results are expected in late 2024, with analysts anticipating data that could ...